Our data strongly support the notion that glucose metabolism, and G-6P transporter UhpC in particular, is targeted by KSK120. This agrees with previous data that suggest that G-6P metabolic processes are critical for Chlamydia infectivity. Thus, KSK120 may prove useful for studying glucose metabolism in Chlamydia spp., and its analogs may also be useful in other intracellular bacteria. Importantly, host G-6P is available only to intracellular bacteria and not to those that reside extracellularly. Thus, KSK120 may represent a new class of drugs that can specifically treat infections of intracellular bacterial pathogens such as Chlamydia while leaving the normal bacterial flora unperturbed.